| scholarly article | Q13442814 |
| P50 | author | Caspar M Schwiedrzik | Q48095287 |
| P2093 | author name string | Yi Wang | |
| Martin R Prince | |||
| Henning U Voss | |||
| Pascal Spincemaille | |||
| Caspar M Schwiedrzik | |||
| Winrich A Freiwald | |||
| Julie R White | |||
| Skye Rasmussen | |||
| Kelly M Gillen | |||
| Andrew W Gorman | |||
| Kofi M Deh | |||
| Clark A Fisher | |||
| Ernest Victor Groman | |||
| P2860 | cites work | Quantitative susceptibility mapping of human brain reflects spatial variation in tissue composition | Q24633104 |
| Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation | Q24642901 | ||
| Iron entry in neurons and astrocytes: a link with synaptic activity | Q26825777 | ||
| Rapid pharmacokinetic and biodistribution studies using cholorotoxin-conjugated iron oxide nanoparticles: a novel non-radioactive method | Q27333732 | ||
| Face Patch Resting State Networks Link Face Processing to Social Cognition | Q27346874 | ||
| Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION) | Q28393651 | ||
| Cerebral blood volume MRI with intravascular superparamagnetic iron oxide nanoparticles. | Q30580013 | ||
| Algorithm for fast monoexponential fitting based on Auto-Regression on Linear Operations (ARLO) of data | Q30784862 | ||
| MRI detection of ferritin iron overload and associated neuronal pathology in iron regulatory protein-2 knockout mice | Q30784995 | ||
| Uptake and metabolism of iron oxide nanoparticles in brain cells. | Q30835947 | ||
| Quantitative susceptibility mapping (QSM): Decoding MRI data for a tissue magnetic biomarker | Q30837513 | ||
| Multiple sclerosis lesion geometry in quantitative susceptibility mapping (QSM) and phase imaging. | Q30846734 | ||
| Simultaneous phase unwrapping and removal of chemical shift (SPURS) using graph cuts: application in quantitative susceptibility mapping | Q30860083 | ||
| Quantitative MR susceptibility mapping using piece-wise constant regularized inversion of the magnetic field | Q33371903 | ||
| Magnetic susceptibility mapping of brain tissue in vivo using MRI phase data | Q33512947 | ||
| Quantitative susceptibility map reconstruction from MR phase data using bayesian regularization: validation and application to brain imaging | Q33517036 | ||
| Susceptibility mapping in the human brain using threshold-based k-space division. | Q34113028 | ||
| Waxholm Space atlas of the Sprague Dawley rat brain | Q34159615 | ||
| The NMR phased array | Q34279090 | ||
| Calculation of susceptibility through multiple orientation sampling (COSMOS): a method for conditioning the inverse problem from measured magnetic field map to susceptibility source image in MRI. | Q34908302 | ||
| A pilot trial of deferiprone for neurodegeneration with brain iron accumulation | Q35528710 | ||
| The metabolism of neuronal iron and its pathogenic role in neurological disease: review | Q35754462 | ||
| In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles | Q36289257 | ||
| Reproducibility of quantitative susceptibility mapping in the brain at two field strengths from two vendors | Q36322681 | ||
| Whole-agent selectivity within the macaque face-processing system | Q36332082 | ||
| Contrast-enhanced functional blood volume imaging (CE-fBVI): enhanced sensitivity for brain activation in humans using the ultrasmall superparamagnetic iron oxide agent ferumoxytol | Q36336562 | ||
| The choroid plexus-cerebrospinal fluid system: from development to aging. | Q36339251 | ||
| Dosage determination of ultrasmall particles of iron oxide for the delineation of microvasculature in the Wistar rat brain | Q36379475 | ||
| High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms using ferumoxytol, a superparamagnetic iron oxide nanoparticle | Q36842826 | ||
| Physicochemical characterization of ultrasmall superparamagnetic iron oxide particles (USPIO) for biomedical application as MRI contrast agents. | Q37059902 | ||
| Magnetic nanoparticles in MR imaging and drug delivery. | Q37192908 | ||
| Quantitative assessment of microvasculopathy in arcAβ mice with USPIO-enhanced gradient echo MRI | Q37229667 | ||
| Ferumoxytol enhanced resting state fMRI and relative cerebral blood volume mapping in normal human brain | Q37275044 | ||
| Iron oxide particles for atheroma imaging | Q37396750 | ||
| Brain iron homeostasis, the choroid plexus, and localization of iron transport proteins. | Q37457294 | ||
| Vascular Imaging With Ferumoxytol as a Contrast Agent. | Q37458797 | ||
| Layer-dependent BOLD and CBV-weighted fMRI responses in the rat olfactory bulb | Q37662741 | ||
| Human brain atlas for automated region of interest selection in quantitative susceptibility mapping: application to determine iron content in deep gray matter structures | Q37664896 | ||
| Nanoparticles in gene therapy principles, prospects, and challenges | Q37957335 | ||
| Self-protecting core-shell magnetic nanoparticles for targeted, traceable, long half-life delivery of BCNU to gliomas. | Q39529747 | ||
| R2 and R2* mapping for sensing cell-bound superparamagnetic nanoparticles: in vitro and murine in vivo testing | Q40082300 | ||
| Morphology enabled dipole inversion for quantitative susceptibility mapping using structural consistency between the magnitude image and the susceptibility map. | Q40281880 | ||
| Nonlinear regularization for per voxel estimation of magnetic susceptibility distributions from MRI field maps | Q40676938 | ||
| Quantitative Susceptibility Mapping at 3 T and 1.5 T: Evaluation of Consistency and Reproducibility. | Q41032097 | ||
| Cell trafficking through the choroid plexus | Q41196854 | ||
| Reducing the object orientation dependence of susceptibility effects in gradient echo MRI through quantitative susceptibility mapping | Q41341482 | ||
| Transport of iron in the blood-brain-cerebrospinal fluid system. | Q41540088 | ||
| FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease | Q43143474 | ||
| Transverse relaxivity of particulate MRI contrast media: From theories to experiments | Q43697920 | ||
| Manganese distribution across the blood-brain barrier. II. Manganese efflux from the brain does not appear to be carrier mediated | Q44300763 | ||
| Ultrasmall supraparamagnetic iron oxide-enhanced magnetic resonance imaging of antigen-induced arthritis: a comparative study between SHU 555 C, ferumoxtran-10, and ferumoxytol | Q44653398 | ||
| Inhaled fluorescent magnetic nanoparticles induced extramedullary hematopoiesis in the spleen of mice. | Q45887932 | ||
| Physicochemical properties of ferumoxytol, a new intravenous iron preparation. | Q46035109 | ||
| Toxicity and tissue distribution of magnetic nanoparticles in mice. | Q46764075 | ||
| Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. | Q46793159 | ||
| Nonlinear formulation of the magnetic field to source relationship for robust quantitative susceptibility mapping | Q47925584 | ||
| Selective iron chelation in Friedreich ataxia: biologic and clinical implications | Q48231374 | ||
| Repeated fMRI using iron oxide contrast agent in awake, behaving macaques at 3 Tesla | Q48595982 | ||
| Evaluation of an fMRI USPIO-based assay in healthy human volunteers. | Q50618185 | ||
| First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)-based blood pool agent. | Q51564012 | ||
| Long term in vivo biotransformation of iron oxide nanoparticles | Q57559352 | ||
| Age-associated lesions in barrier-reared male Sprague-Dawley rats: a comparison between Hap: (SD) and Crl:COBS[R]CD[R](SD) stocks | Q72536826 | ||
| MR choroid plexus sign of iron overload | Q73213858 | ||
| Application of the static dephasing regime theory to superparamagnetic iron-oxide loaded cells | Q74447798 | ||
| Pharmacokinetic and hemodynamic safety of two superparamagnetic agents, Endorem and Sinerem, in cirrhotic rats | Q74483531 | ||
| Structure, chemistry, and pharmacokinetics of intravenous iron agents | Q81110731 | ||
| Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent | Q82567702 | ||
| Transfusional iron overload presenting as choroid plexus hemosiderosis | Q87422365 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 139-147 | |
| P577 | publication date | 2018-04-01 | |
| 2019-03-01 | |||
| P1433 | published in | Comparative Medicine | Q15756205 |
| P1476 | title | Brain Iron Distribution after Multiple Doses of Ultra-small Superparamagnetic Iron Oxide Particles in Rats | |
| Brain Iron Distribution after Multiple Doses of Ultra-small Superparamagnetic Iron Oxide Particles in Rats. | |||
| P478 | volume | 68 |
Search more.